幽门螺杆菌感染损害癌症免疫治疗疗效
该研究通过小鼠模型和人类回顾性队列,探究幽门螺杆菌感染对癌症免疫治疗疗效的影响。小鼠中感染削弱免疫检查点抑制剂和疫苗疗效,肿瘤特异性CD8+ T细胞减少;非小细胞肺癌患者中幽门螺杆菌血清阳性与抗PD-1治疗生存期缩短相关。
要点
- 幽门螺杆菌感染削弱小鼠对免疫检查点抑制剂和疫苗的应答
- 感染小鼠肿瘤内肿瘤特异性CD8+ T细胞数量和活化状态下降
- 非小细胞肺癌中幽门螺杆菌血清阳性与抗PD-1治疗生存期缩短相关
核心结论
- 幽门螺杆菌感染对癌症免疫治疗疗效有负面影响,血清学可能用于个性化免疫治疗。
研究设计与样本
- 小鼠模型评估免疫检查点抑制剂或疫苗对幽门螺杆菌感染小鼠肿瘤体积的影响。
- 人类回顾性研究在两个独立队列中评估幽门螺杆菌血清阳性与非小细胞肺癌抗PD-1治疗疗效的相关性。
主要发现
- 感染小鼠接受抗CTLA-4和/或抗PD-L1或抗癌疫苗治疗后肿瘤体积显著大于未感染小鼠。
- 感染小鼠肿瘤中肿瘤特异性CD8+ T细胞数量和活化状态下降,独立于肠道微生物组组成。
- 感染小鼠树突状细胞在体外共培养中促进肿瘤特异性CD8+ T细胞增殖的能力较低。
- Dijon队列中幽门螺杆菌血清阳性非小细胞肺癌患者抗PD-1治疗中位生存期6.7个月,血清阴性15.4个月(p=0.001)。
- Montreal队列中幽门螺杆菌血清阳性与非小细胞肺癌抗PD-1治疗无进展生存期 apparent decrease 相关。
临床怎么用
- 考虑在癌症免疫治疗前检测幽门螺杆菌血清学以指导个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this study, we determined whether Helicobacter pylori (H. pylori) infection dampens the efficacy of cancer immunotherapies. DESIGN: Using mouse models, we evaluated whether immune checkpoint inhibitors or vaccine-based immunotherapies are effective in reducing tumour volumes of H. pylori-infected mice. In humans, we evaluated the correlation between H. pylori seropositivity and the efficacy of the programmed cell death protein 1 (PD-1) blockade therapy in patients with non-small-cell lung cancer (NSCLC). RESULTS: In mice engrafted with MC38 colon adenocarcinoma or B16-OVA melanoma cells, the tumour volumes of non-infected mice undergoing anticytotoxic T-lymphocyte-associated protein 4 and/or programmed death ligand 1 or anti-cancer vaccine treatments were significantly smaller than those of infected mice. We observed a decreased number and activation status of tumour-specific CD8+ T cells in the tumours of infected mice treated with cancer immunotherapies independent of the gut microbiome composition. Additionally, by performing an in vitro co-culture assay, we observed that dendritic cells of infected mice promote lower tumour-specific CD8+ T cell proliferation. We performed retrospective human clinical studies in two independent cohorts. In the Dijon cohort, H. pylori seropositivity was found to be associated with a decreased NSCLC patient survival on anti-PD-1 therapy. The survival median for H. pylori seropositive patients was 6.7 months compared with 15.4 months for seronegative patients (p=0.001). Additionally, in the Montreal cohort, H. pylori seropositivity was found to be associated with an apparent decrease of NSCLC patient progression-free survival on anti-PD-1 therapy. CONCLUSION: Our study unveils for the first time that the stomach microbiota affects the response to cancer immunotherapies and that H. pylori serology would be a powerful tool to personalize cancer immunotherapy treatment.
引用
- Oster P, Vaillant L, Riva E, et al. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 2021. PMID: 34253574. doi:10.1136/gutjnl-2020-323392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。